CMS Reaffirms MSA Inclusion of Two Major Rx Groups in MSAs

CMS announces Benzodiazepine and Barbiturate coverage under Medicare Part D in the treatment of specific conditions

As of January 1, 2013, CMS implemented a decision to include and cover two major drug groups under Medicare Part D: benzodiazepines when used for medically-accepted indications and barbiturates when used in the treatment of epilepsy, cancer, or chronic mental health disorders.

NuQuest/Bridge Pointe (NQBP) has been including these drugs in our MSAs, as appropriate, as of January 1, 2013. However, the new WCRC has been inconsistent with its reviews and approval of these drugs when included in a MSA allocation. Read more about this important decision…

Leave a Reply